Literatur
-
1 American Heart Association .Heart Disease and Stroke Statistics - 2006 Update. Dallas, Texas; American Heart Association 2006
-
2
Rich M W.
Management of heart failure in the elderly.
Heart Fail Rev.
2002;
7
89-97
-
3
Koelling T M, Chen R S, Lubwama R N. et al .
The expanding national burden of heart failure in the United States: the influence of heart failure in women.
Am Heart J.
2004;
147
74-78
-
4
Levy D, Kenchaiah S, Larson M G. et al .
Long-term trends in the incidence of and survival with heart failure.
N Engl J Med.
2002;
347
1397-1402
-
5
Young J B, Dunlap M E, Pfeffer M A. et al .
Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Results of the CHARM low left ventricular ejection fraction trials.
Circulation.
2004;
110
2618-2626
-
6
Fonarow G C, Abraham W T, Albert N M. et al .
Association between performance measures and clinical outcomes for patients hospitalised with heart failure.
JAMA.
2007;
297
61-70
-
7 Fact Sheet Herzinsuffizienz 2005. http://www.knhi.de/html/Publikationen/publikationen.htm
-
8
Fischer M, Baessler A, Holmer S R. et al .
Epidemiologie der linksventrikulären Dysfunktion in der Allgemeinbevölkerung Deutschlands. Echokardiographische Untersuchungen einer großen Bevölkerungsstichprobe.
Z Kardiol.
2003;
92
294-302
-
9
Störk S, Angermann C E.
Das Interdisziplinäre Netzwerk Herzinsuffizienz. Versorgungsforschung und Krankheitsmanagement.
Gesundheit und Gesellschaft Wissenschaft.
2007;
7
14-22
-
10 Gesundheitsberichterstattung des Bundes;. http://www.gbe-bund.de
-
11
Hoppe U C, Böhm M, Dietz R. et al .
Leitlinie zur Therapie der chronischen Herzinsuffizienz.
Z Kardiol.
2005;
94
488-509
-
12
Kannel W P, Wolf P A, Verter J.
Manifestations of coronary heart disease predisposing to stroke. The Framingham study.
JAMA.
1983;
250
2942-2946
-
13
Dunkman W B, Johnson G R, Carson P E. et al .
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation.
1993;
87
V194-V201
-
14
Siachos T, Vanbakel A, Feldman D S. et al .
Silent strokes in patients with heart failure.
J Cardiac Fail.
2005;
11
485-489
-
15
Pullicino P, Thompson J LP, Barton B. et al .
Warfarin versus Aspirin in Patients with Reduced Cardiac Ejection Fraction (WARCEF): Rationale, Objectives, and Design.
J Cardiac Fail.
2006;
12
39-46
-
16
Dries D L, Rosenberg Y D, Waclawiw M A. et al .
Ejection fraction and risk of thromboembolic events in patient with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials.
J Am Coll Cardiol.
1997;
29
1074-1080
-
17
Loh E, Sutton M SJ, Wun C CC. et al .
Ventricular dysfunction and the risk of stroke after myocardial infarction.
N Engl J Med.
1997;
336
251-257
-
18
Katz S D, Marantz P R, Biasucci L. et al .
Low incidence of stroke in ambulatory patients with heart failure: a prospective study.
Am Heart J.
1993;
126
141-146
-
19
Cioffi G, Pozzoli M, Forni G. et al .
Systemic thromboembolism in chronic heart failure.
Eur Heart J.
1996;
17
1381-1389
-
20
The CONSENSUS Trial Study Group .
Effects of enalapril on mortality in severe heart failure.
N Engl J Med.
1987;
316
1429-1435
-
21
Adams Jr H P, Bendixen B H, Kappelle L J. et al .
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
Stroke.
1993;
24
35-41
-
22
Fuster V, Halperin J L.
Left ventricular thrombi and cerebral embolism.
N Engl J Med.
1989;
320
392-394
-
23
Dries D L, Exner D V, Gersh B J. et al .
Racial differences in the outcome of left ventricular dysfunction.
N Engl J Med.
1999;
340
609-616
-
24
Sacco R L, Shi T, Zamanillo M C. et al .
Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan stroke study.
Neurology.
1994;
44
626-634
-
25
Petty G W, Brown R D, Whisnant Jr J P. et al .
Survival and recurrence after first cerebral infarction - a population-based study in Rochester, Minnesota, 1975 through 1989.
Neurology.
1998;
50
208-216
-
26
Harvey W P, Finch C A.
Dicumarol prophylaxis of thromboembolic disease in congestive heart failure.
N Engl J Med.
1950;
242
208-211
-
27
Griffith G C, Stragnell R, Levinson D C. et al .
A study of the beneficial effects of anticoagulant therapy in congestive heart failure.
Ann Int Med.
1952;
37
867-887
-
28
Anderson G M, Hull E.
The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure.
Am Heart J.
1950;
9
697-702
-
29
Smith P, Arnesen H, Holme I.
The effect of warfarin on mortality and reinfarction after myocardial infarction.
N Engl J Med.
1990;
323
147-152
-
30
Anticoagulants in the Secondary Prevention of Eventsin Coronary Thrombosis (ASPECT) Research Group .
Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction.
Lancet.
1994;
343
499-503
-
31
Sixties Plus Reinfarction Study Research Group .
A double-blind trial to assess long-term oral anticoagulation therapy in elderly patients after myocardial infarction.
Lancet.
1980;
ii
989-994
-
32
Massie B M, Krol W F, Ammon S E. et al .
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
J Card Fail.
2004;
10
101-112
-
33
Freudenberger R S, Massie B M.
Silent cerebral infarction in heart failure: vascular or thromboembolic?.
J Cardiac Fail.
2005;
11
490-491
-
34
Massie B M.
Aspirin Use in chronic heart failure.
J Am Coll Cardiol.
2005;
46
963-966
-
35
Anand S S, Yusus S.
Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.
JAMA.
1999;
282
2058-2067
-
36
Antiplatelets Trialists’ Collaboration .
Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
BMJ.
1994;
308
81-106
-
37
Al-Khadra A S, Salem D N, Rand W M. et al .
Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Trial.
J Am Coll Cardiol.
1998;
31
419-425
-
38
Leor J, Reicher-Reiss H, Goldbourt U. et al .
Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors.
J Am Coll Cardiol.
1999;
33
1920-1925
Dr. Dr. med. Mathias Rauchhaus
Medizinische Klinik mit Schwerpunkt für Kardiologie, Campus Virchow-Klinikum (CVK)
Charité, Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
eMail: mathias.rauchhaus@charite.de
